**London**: At the LogiPharma conference, Steffen Lang from Novartis discussed the company’s ongoing efforts to refine operations for next-generation therapies, emphasising technological integration, sustainability, and collaboration to improve patient outcomes and adapt to evolving manufacturing needs.
At the LogiPharma conference, Steffen Lang, representative of Novartis, elaborated on the company’s vision and ongoing transformation efforts aimed at refining operations to enhance the delivery of individualized and next-generation therapies. This dialogue illuminated Novartis’ strategic focus on adapting its manufacturing and distribution processes to cater to the unique requirements of smaller patient populations, a trend evident in contemporary treatments.
Lang articulated the importance of viewing operations not merely as tactical responsibilities but as pivotal enablers of innovation. In an era defined by rapid technological advancements, the company is investing significantly in the right talent and the development of skills necessary to leverage these changes throughout the value chain. The integration of technology is seen as essential in not only improving operational efficiency but also in ensuring compliance with Good Manufacturing Practice (GMP) regulations, maintaining high standards of workplace safety, and guaranteeing reliable supply chains. “We don’t want to miss a single patient,” Lang stated, underscoring the company’s commitment to patient care.
In a landscape where environmental sustainability is gaining importance, Novartis also acknowledges its role and responsibility in this regard. The company is on a long-term journey toward enhancing its sustainable practices, reflecting a growing concern within the pharmaceutical industry about its environmental impact.
Lang highlighted that significant changes within the manufacturing sector have evolved over the last decade and are only expected to accelerate. The process begins with effective planning and forecasting, which are integral to the successful navigation of the entire value chain—from manufacturing to distribution and ultimately to patient delivery. Such an approach ensures that the therapies reach those in need promptly and reliably.
The company is steadfast in its focus on four core therapeutic areas: oncology, cardiovascular and metabolic diseases, neuroscience, and immunology. As Novartis develops its pipeline further, it relies on five key technology platforms, which include small molecules, biologics, cell and gene therapies, xRNA, and radioligand therapies. Lang mentioned the anticipation of introducing a sixth platform in the near future, emphasizing the preparation of operations teams to effectively scale delivery for these emerging products.
Additionally, Lang pointed out the significance of industry collaboration in advancing digital transformation, sustainability initiatives, and workforce training. As Novartis forges ahead in discovering innovative therapies, its commitment to sharing knowledge and fostering collective progress within the pharmaceutical ecosystem remains a priority. This forward-looking approach underscores the company’s vision of improving the lives of patients through enhanced operational strategies and a focus on technological integration.
Source: Noah Wire Services
